期刊文献+

粒细胞集落刺激因子联合化疗治疗老年急性白血病

原文传递
导出
摘要 目的通过对老年急性白血病患者采用粒细胞集落刺激因子(G—CSF)联合化疗的治疗,寻求老年急性白血病较好治疗方案。方法4例急性淋巴细胞白血病采用VDP方案,13例急性髓细胞白血病采用DA方案或MA方案。化疗前1d外周血白细胞〈10.0×10^9/L的骨髓增生明显活跃以下的患者均加用G—CSF 300μg/d皮下注射。白细胞≥10.0×10^9/L的患者在化疗后白细胞〈2.0×10^9/L时加用G—CSF 300μg/d至化疗外周血中性粒细胞水平〉1.0×10^9/L。结果17例患者化疗后CR率58.8%,总有效率76.4%。2例患者治疗早期分别死于急性心梗和消化道大出血,早期死亡率11.7%。中性粒细胞持续〈0.5×10^9/L中位时间18.5d,平均缩短4.5d,结论早期加用G—CSF增加化疗药物对白血病细胞的毒性,提高缓解率,并且缩短中性粒细胞减少或缺乏的时间,减少感染的机会。
出处 《中国医师杂志》 CAS 2009年第1期124-125,共2页 Journal of Chinese Physician
  • 相关文献

参考文献5

  • 1Tallman MS. New strategies for the treatment of acutemyeloid leukemia including antibodies and other novelagents. Hematology Am Soc Hematol Educ Program, 2005 : 143-150.
  • 2Kanntarjian H, O'brien S,Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65years or older with acute myeloid leukemia or high-riskmyelodysplastic syndeome : predictive prognosticmodels for outcome. Cancer, 2006, 106: 1090-1098.
  • 3钱思轩,李建勇,沈云峰,蒋元强,陆化,吴汉新,徐卫,程蕴琳,盛瑞兰.CAG预激方案治疗老年人急性髓细胞白血病的临床观察[J].中华老年医学杂志,2007,26(4):248-250. 被引量:39
  • 4Saito K, Nakamura Y, Aoyagi M, et al. Low-dosecytarabine and aclarubicin in combination with granulocyte colony-stimulating factor ( CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (aml) and previously untreated elderly patients with AML, and refractory anemia with excess blasts in transformation. Int J Hematol, 2000,71:238-244.
  • 5Hofmann WK, Heil G, Zander C, et al. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and hingh-risk acute myeloid leukemia. Ann Hematol, 2004, 83:498-503.

二级参考文献7

  • 1Tallman MS. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Hematology Am Soc Hematol Educ Program,2005,143-150.
  • 2Kantarjian H, O'brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer, 2006,106: 1090-1098.
  • 3Saito K, Nakamura Y, Aoyagi M, et al. Low-dose cytarabine and aclarubicin in combination withgranulocyte colony-stimulating factor (CAG regimen)for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML,secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol, 2000, 71:238-244.
  • 4Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic eytogeneties on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 Trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood,1998,92: 2322-2333.
  • 5Miller AB, Hooqstraten MB, Staquet M, et al. Reporting results of cancer treatment. Cancer,1981,47 :207-214.
  • 6Hofmann WK, Heil G, Zander C, et al. Intensive chemotherapy with idarubicin, cytarabine, etoposide,and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol, 2004, 83:498-503.
  • 7Lang K, Earle CC, Foster T, et al, Trends in the treatment of acute myeloid leukemia in the elderly. Drug Aging, 2005,22:943-955.

共引文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部